Cargando…

Clinical Characteristics and Prognosis of Bloodstream Infection with Carbapenem-Resistant Pseudomonas aeruginosa in Patients with Hematologic Malignancies

OBJECTIVE: To analyze the clinical characteristics and prognostic risk factors of carbapenem-resistant Pseudomonas aeruginosa (CRPA) bloodstream infections in patients with hematologic malignancies. METHODS: Medical records and drug susceptibility data of patients with hematologic malignancies compl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Fangfang, Xiao, Weiqiang, Wang, Xiaokun, Fu, Yuewen, Wei, Xudong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402715/ https://www.ncbi.nlm.nih.gov/pubmed/37546370 http://dx.doi.org/10.2147/IDR.S419064

Ejemplares similares

P1527: ASSESSMENT OF RISK FACTORS AND ANTIMICROBIAL THERAPY FOR CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA BLOODSTREAM INFECTIONS IN HEMATOLOGICAL PATIENTS
por: Chen, Zhangjie, et al.
Publicado: (2023)

Risk Factors and Outcomes of Patients with Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infection
por: Wei, Xianzhen, et al.
Publicado: (2023)

Risk factors and influence of carbapenem exposure on the development of carbapenem resistant Pseudomonas aeruginosa bloodstream infections and infections at sterile sites
por: Barron, Michelle A., et al.
Publicado: (2016)

Clinical Characteristics and Risk Factors for Bloodstream Infection Due to Carbapenem-Resistant Klebsiella pneumoniae in Patients with Hematologic Malignancies
por: Zhang, Piaopiao, et al.
Publicado: (2020)

Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors
por: Royo-Cebrecos, Cristina, et al.
Publicado: (2022)

Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases
por: Zhen, Sisi, et al.
Publicado: (2023)

Resistance of Animal Strains of Pseudomonas aeruginosa to Carbapenems
por: Haenni, Marisa, et al.
Publicado: (2017)

Risk Factors for Mortality and Outcomes in Hematological Malignancy Patients with Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections
por: Meng, Haiyang, et al.
Publicado: (2022)

Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study
por: Terahara, Fumitaka, et al.
Publicado: (2019)

A Visualized Mortality Prediction Score Model in Hematological Malignancies Patients with Carbapenem-Resistant Organisms Bloodstream Infection
por: Qian, Chenjing, et al.
Publicado: (2023)

Therapeutic Management of Pseudomonas aeruginosa Bloodstream Infection Non-Susceptible to Carbapenems but Susceptible to “Old” Cephalosporins and/or to Penicillins
por: Zaidenstein, Ronit, et al.
Publicado: (2018)

Epidemiology and mortality outcome of carbapenem- and colistin-resistant Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa bloodstream infections
por: Balkhair, A., et al.
Publicado: (2023)

Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China
por: Lan, Peng, et al.
Publicado: (2022)

High risk of bloodstream infection of carbapenem-resistant enterobacteriaceae carriers in neutropenic children with hematological diseases
por: Liu, Li-Peng, et al.
Publicado: (2023)

Carbapenem Susceptibility and Multidrug-Resistance in Pseudomonas aeruginosa Isolates in Egypt
por: Hashem, Hany, et al.
Publicado: (2016)

Spread of Carbapenem Resistance by Transposition and Conjugation Among Pseudomonas aeruginosa
por: van der Zee, Anneke, et al.
Publicado: (2018)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Risk factors and outcomes of inpatients with carbapenem-resistant Pseudomonas aeruginosa bloodstream infections in China: a 9-year trend and multicenter cohort study
por: Yuan, Qing, et al.
Publicado: (2023)

Long-Term Dominance of Carbapenem-Non-Susceptible Pseudomonas aeruginosa ST111 in Hematologic Malignancy Patients and Hematopoietic Cell Transplant Recipients
por: Zhang, Liyang, et al.
Publicado: (2022)

Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
por: Garcia, Rebeca Carvalho Lacerda, et al.
Publicado: (2023)

Epidemiological and Genetic Characteristics of Clinical Carbapenem-Resistant Pseudomonas aeruginosa Strains in Guangdong Province, China
por: Zhao, Yonggang, et al.
Publicado: (2023)

Vaccination to Prevent Pseudomonas aeruginosa Bloodstream Infections
por: Hart, Robert J., et al.
Publicado: (2022)

Anti-bacterial mechanism of baicalin-tobramycin combination on carbapenem-resistant Pseudomonas aeruginosa
por: Jin, Li-Min, et al.
Publicado: (2023)

Breakthrough Bacteremia with Meropenem-resistant Pseudomonas aeruginosa in Hematologic Malignancy Patients Receiving Levofloxacin Prophylaxis
por: Hakki, Morgan, et al.
Publicado: (2017)

Correlation Between Virulence Genotype and Fluoroquinolone Resistance in Carbapenem-Resistant Pseudomonas aeruginosa
por: Cho, Hye Hyun, et al.
Publicado: (2014)

Detection of Metallo-Beta Lactamases Among Carbapenem-Resistant Pseudomonas aeruginosa
por: Farajzadeh Sheikh, Ahmad, et al.
Publicado: (2014)

Carbapenem-resistant Pseudomonas aeruginosa: association with virulence genes and biofilm formation
por: Rossi Gonçalves, Iara, et al.
Publicado: (2016)

Risk Factors for Carbapenem-Resistant Pseudomonas aeruginosa, Zhejiang Province, China
por: Hu, Yan-Yan, et al.
Publicado: (2019)

Challenges of Carbapenem-resistant Pseudomonas aeruginosa in Infection Control and Antibiotic Management
por: Kim, Young Jin, et al.
Publicado: (2024)

The Threat of Carbapenem-Resistant Gram-Negative Bacteria in Patients with Hematological Malignancies: Unignorable Respiratory Non-Fermentative Bacteria-Derived Bloodstream Infections
por: Lu, Linli, et al.
Publicado: (2022)

Infections Due to Carbapenem-Resistant Bacteria in Patients With Hematologic Malignancies
por: Lalaoui, Rym, et al.
Publicado: (2020)

A retrospective analysis of Pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible infections
por: Shi, Qingyi, et al.
Publicado: (2019)

Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study
por: Vivo, Amanda, et al.
Publicado: (2022)

Multidrug-Resistant Pseudomonas Aeruginosa Bloodstream Infections: Analysis of Trends in Prevalence and Epidemiology
por: Tacconelli, Evelina, et al.
Publicado: (2002)

Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections
por: Tschudin-Sutter, Sarah, et al.
Publicado: (2018)

2566. infection Dynamics of Pseudomonas aeruginosa Bloodstream Infections
por: Bachta, Kelly E R, et al.
Publicado: (2019)

Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas aeruginosa
por: Kosai, Kosuke, et al.
Publicado: (2018)

Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas Aeruginosa
por: Kosai, Kosuke, et al.
Publicado: (2017)

Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015
por: Walters, Maroya Spalding, et al.
Publicado: (2019)

Mechanisms for Rapid Evolution of Carbapenem Resistance in a Clinical Isolate of Pseudomonas aeruginosa
por: Xu, Congjuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ocind7g5k4s63tfj5p3poep306